SAINT® TMS vs Neurofeedback for Depression: Evidence & Comparison
SAINT® TMS and neurofeedback are both non-invasive, brain-targeted therapies, but they differ fundamentally in mechanism, FDA status, clinical evidence, and treatment duration. SAINT® is an FDA-cleared, physician-supervised protocol that delivers 50 high-intensity magnetic stimulation sessions in 5 days, personalized via 3T resting-state fMRI, with 79% remission documented in a sham-controlled randomized trial. Neurofeedback is an active brain-wave training technique (EEG operant conditioning) requiring 20 to 40 sessions over several months. In current FDA databases, neurofeedback devices are cleared for relaxation and stress reduction, but none is FDA-cleared or approved to treat depression.
Key takeaways
- FDA Status: SAINT® is FDA-cleared (K220177) for major depressive disorder with Breakthrough Device designation; no neurofeedback device is FDA-cleared for depression (cleared for relaxation and stress reduction only).
- Mechanism: SAINT® passively stimulates and depolarizes prefrontal cortical neurons with magnetic fields; neurofeedback requires active mental effort to alter EEG brain waves via feedback.
- Time Commitment: SAINT® completes 50 sessions in 5 consecutive business days; neurofeedback typically requires 20 to 40 sessions spread across 8 to 16 weeks.
- Targeting: SAINT® uses individual 3T resting-state fMRI to target the anti-correlated sgACC-dlPFC circuit; neurofeedback uses surface scalp electrodes (e.g., F3/F4 alpha asymmetry).
- Evidence Base: SAINT® is supported by double-blind randomized sham-controlled trial data (Cole et al., 2022); neurofeedback studies for depression are mostly small, open-label, and heterogeneous.
- Insurance: Major insurers classify neurofeedback for depression as investigational; TMS has established coverage guidelines.
Overview: Direct Stimulation vs Brain-Wave Training
Patients searching for non-pharmacological, brain-based depression treatments frequently encounter both TMS and neurofeedback. Both avoid oral medications and systemic drug side effects, but they operate through contrasting physiological models.
Neurofeedback treats the brain as a student: it measures electrical signals with surface sensors and rewards the patient when their brain waves match a healthier frequency. SAINT® treats the brain as an electrical circuit: it directly applies magnetic energy to activate underperforming neural connections between the prefrontal cortex and deep emotional hubs.
Side-by-Side Comparison: SAINT® vs Neurofeedback
The table below summarizes key differences in regulation, evidence, clinical burden, and costs:
| Feature | SAINT® Accelerated TMS | EEG Neurofeedback (Biofeedback) |
|---|---|---|
| Primary Action | Passive magnetic depolarization of deep prefrontal-subgenual circuits | Active self-regulation of brain-wave rhythms via visual/auditory feedback |
| FDA Clearance for Depression | Cleared (K220177) specifically for Major Depressive Disorder (TRD) | None. Regulated as biofeedback for relaxation and stress reduction (21 CFR 882.5050) |
| Protocol Duration | 5 consecutive days (10 sessions/day, 50 total sessions) | 8 to 16 weeks (20 to 40 sessions, 2–3 visits/week) |
| Patient Engagement | Passive: relax comfortably in chair while coil delivers pulses | Active: focused mental effort, playing computer games or watching screens |
| Targeting Method | Individualized 3T resting-state fMRI targeting sgACC-dlPFC node | 10-20 EEG electrode placement (e.g. frontal alpha asymmetry) |
| Pivotal Evidence | Double-blind sham-controlled RCT: 79% remission (Cole et al., 2022) | Systematic reviews (Trambaiolli 2021, Xia 2024): mixed small studies; lack large sham trials |
| Insurance Classification | TMS covered by Medicare & commercial payers; SAINT® case-by-case | Classified as 'experimental, investigational, or unproven' for depression (e.g., Aetna) |
| Out-of-Pocket Cost | Starts at $25,000 (all-inclusive 5-day week, fMRI, physician oversight) | Typically $3,000 to $8,000 for a full multi-month series |
FDA Regulatory Status: What the Official Records Show
Understanding FDA terminology is essential when evaluating mental health technologies:
• TMS and SAINT®: The FDA first authorized TMS for depression in 2008 (NeuroStar, De Novo DEN070003). In September 2022, the FDA granted 510(k) clearance (K220177) to the Magnus Medical SAINT Neuromodulation System specifically for major depressive disorder in adults who have failed prior antidepressant therapy, following an earlier Breakthrough Device designation.
• Neurofeedback: Neurofeedback devices are classified under 21 CFR 882.5050 as Class II biofeedback devices. In the FDA database as of late 2026, clearances include IASIS i2 (K252923, March 2026) for 'relaxation and stress reduction' and Prism (K222101, March 2023) for relaxation and as an adjunct for PTSD symptoms. Searches of FDA De Novo and 510(k) databases confirm that zero neurofeedback devices have been reviewed or cleared specifically for treating depression. While clinicians may legally use biofeedback off-label, insurers typically decline coverage due to the absence of FDA clearance for depression.
Clinical Evidence Comparison
The difference in scientific validation between the two approaches is substantial:
In the pivotal double-blind randomized controlled trial of the SAINT® protocol published in The American Journal of Psychiatry (Cole et al., 2022), 79% of patients with severe treatment-resistant depression achieved clinical remission (defined as MADRS ≤ 10) compared to just 11% in the sham stimulation group. Benefits were visible within days.
For neurofeedback, while research has been conducted for decades, published reviews (such as Trambaiolli et al., 2021 in Neuroscience & Biobehavioral Reviews and Xia et al., 2024 in Cerebral Cortex) emphasize that the field is constrained by small sample sizes, lack of standardized training protocols, and inconsistent sham controls. No head-to-head randomized trial has ever demonstrated that neurofeedback matches the efficacy or speed of accelerated TMS in treatment-resistant depression.
Who Each Approach Fits
Neurofeedback may appeal to: Individuals seeking non-invasive stress reduction, general cognitive training, or mild anxiety management who have ample time (several months) and do not have acute or treatment-resistant depression.
SAINT® Accelerated TMS is indicated for: Adults with moderate to severe major depression who have not achieved adequate relief after trying one or more antidepressant medications, who require fast symptom improvement, or who cannot afford to take weeks off work for daily appointments. Learn if you are a candidate or explore how to pay for SAINT®.
Understanding SAINT® TMS: How It Works & What to Expect
SAINT® is an FDA-cleared treatment for adults with major depressive disorder who have not improved on antidepressants in the current episode. These videos explain how it works and how it differs from conventional TMS.
SAINT® is an FDA-cleared, fMRI-guided form of TMS developed at Stanford. Most patients complete treatment in one week — not the six weeks standard TMS requires.
Follow a real patient through the five-day SAINT® treatment week
Is SAINT® TMS Right for You?
Tried antidepressants without enough relief? SAINT® TMS is an FDA-cleared, fMRI-guided treatment for adults with major depressive disorder who have not improved enough with antidepressant medication.
SAINT® uses a personalized brain target and delivers treatment over five consecutive days. It differs from standard TMS in its targeting approach, treatment schedule, and research background. In a small randomized trial, 11 of 14 people receiving active treatment reached remission at the four-week assessment, compared with 2 of 15 receiving sham treatment. Results vary, and a five-day treatment course does not guarantee remission in five days.
How SAINT® Works and How It Differs From Conventional TMS
SAINT® is an FDA-cleared treatment for adults with major depressive disorder who have not improved on antidepressants in the current episode. This video explains how it works, and how it differs from conventional TMS.
Conventional TMS usually means about 30 visits over 6 to 9 weeks. SAINT is five visits over five days.
What makes it different: SAINT® uses an fMRI brain scan to personalize the stimulation target to your individual brain. A 45-minute scan maps your brain and identifies the specific circuit linked to depression. Treatment is then delivered as ten 10-minute sessions per day, with 50-minute breaks between them, across five consecutive days.
In clinical trials, 79% of participants reached remission, with an average of 2.6 days to remission. SAINT is generally well tolerated; the most common side effects reported were mild headache and temporary scalp discomfort at the treatment site.
SAINT® at Neuro Wellness TMS Centers of America
Coral Springs, Florida
Free benefits check · Self-pay options available
Call or Text: 954-827-9793
Sources: Cole et al., American Journal of Psychiatry 2020;177:716-726 and 2022;179(2):132-141. magnusmedical.com/depression-therapy. PubMed 34711062. FDA 510(k) K220177.
Insurance coverage for SAINT is currently limited and varies by plan. Individual results may vary. This video is educational and is not medical advice. Talk to a qualified clinician about whether SAINT is appropriate for you. If you are in crisis, call or text 988.
Frequently Asked Questions
Is neurofeedback FDA-approved or cleared for depression?
No neurofeedback device is FDA-cleared or approved specifically to treat depression. In current FDA device databases (searched through late 2026), neurofeedback systems are regulated as biofeedback devices (21 CFR 882.5050) cleared for 'relaxation and stress reduction' (such as IASIS i2, 510(k) K252923 in March 2026) or as an adjunct for PTSD symptoms (Prism, K222101 in 2023). None holds a cleared indication for Major Depressive Disorder. By contrast, SAINT® on the Magnus Neuromodulation System holds FDA clearance (K220177) and Breakthrough Device designation specifically for treatment-resistant major depression.
What is the core difference in how neurofeedback and SAINT® work?
Neurofeedback is an active brain-training method: scalp sensors read your EEG brain waves, and you learn to voluntarily modulate your own brain activity through real-time audio or visual rewards (operant conditioning). SAINT® is a direct, passive neuromodulation therapy: an electromagnetic coil delivers focused magnetic pulses that induce intracranial electrical currents to depolarize prefrontal neurons and normalize connectivity with the subgenual cingulate, without requiring conscious effort or learning.
How long does each treatment take to complete?
SAINT® is completed in 5 consecutive business days (10 sessions per day, 50 sessions total). A typical neurofeedback course requires 20 to 40 individual sessions delivered 2 to 3 times per week, requiring 8 to 16 weeks (2 to 4 months) to complete.
Does insurance cover neurofeedback for depression?
Virtually all major commercial health plans and Medicare consider neurofeedback (EEG biofeedback) for depression to be experimental, investigational, or unproven (for example, Aetna Clinical Policy Bulletin 0132). As a result, neurofeedback is almost exclusively out-of-pocket ($3,000 to $8,000). TMS has broad insurance coverage policies for treatment-resistant depression, and SAINT® coverage is reviewed on a case-by-case prior authorization basis.
Can neurofeedback and TMS or SAINT® be combined?
Some clinics offer neurofeedback alongside TMS. However, clinical research combining the two in depression is extremely limited—confined to isolated case reports. There is no randomized evidence demonstrating that adding neurofeedback to an evidence-based protocol like SAINT® produces superior clinical outcomes.
Cited Research
- 1. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022;179(2):132-141.
- 2. Trambaiolli LR, Kohl SH, Monte-Serrat DM, et al. Neurofeedback training in major depressive disorder: a systematic review of clinical efficacy, study quality and reporting practices. Neurosci Biobehav Rev. 2021;125:33-49.
- 3. Xia Z, et al. Uncovering the power of neurofeedback: a meta-analysis of its effectiveness in treating major depressive disorders. Cereb Cortex. 2024;34(6):bhae256.
- 4. U.S. Food and Drug Administration. 510(k) Premarket Notification K220177 — Magnus Medical SAINT Neuromodulation System.
- 5. Aetna Clinical Policy Bulletin 0132: Biofeedback (last reviewed July 2026).
Important Safety Information
SAINT® TMS is non-invasive and performed under medical supervision. Contraindications include non-removable ferromagnetic metal in or near the head, active seizure disorders, or implanted electronic devices. Neurofeedback carries minimal physical risk, primarily mild session-related headache or mental fatigue. Neither therapy is a guarantee of cure. For 24/7 crisis support, dial or text 988.
SAINT® is delivered only by verified providers on the Magnus Medical system. Programs described as SAINT “alternatives”, “equivalents” or “fMRI-guided accelerated TMS” are not SAINT®, are not affiliated with us, and SAINT® results do not apply to them. Read our SAINT® disclaimer.
Speak with Our Clinical Team About Non-Drug Options
Speak with our clinical team. A free consultation is the best way to get answers specific to your situation.
SAINT® is a registered trademark of Stanford University, exclusively licensed to Magnus Medical, Inc. NWCOA is an independent authorized provider in Coral Springs, FL.
Related Patient Education
SAINT® vs Traditional TMS
Compare 5-day accelerated SAINT® to conventional 6-week TMS
Fast Depression Treatment Options
Compare rapid treatment modalities: SAINT®, ketamine, SPRAVATO®, and TMS
SAINT® vs tDCS
Compare magnetic stimulation to prescription direct current therapy
SAINT® TMS Protocol Explained
50 sessions in 5 days: dosing parameters, rest periods, and fMRI
SAINT® TMS Cost Guide
Complete cost breakdown, insurance verification, and financing options